 This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-371797 versus placebo in treating ankylosing spondylitis, and to further evaluate the drugs safety. Approximately 130 patients from the US, Canada, Poland and Hungary will be enrolled in this study. 